FOSINOPRILAT

First approved in 1991

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H34NO5P
Molecular Weight	435.4935
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)[C@@H]1C[C@H](CN1C(=O)CP(O)(=O)CCCCC2=CC=CC=C2)C3CCCCC3

InChI

InChIKey=WOIWWYDXDVSWAZ-RTWAWAEBSA-N

InChI=1S/C23H34NO5P/c25-22(17-30(28,29)14-8-7-11-18-9-3-1-4-10-18)24-16-20(15-21(24)23(26)27)19-12-5-2-6-13-19/h1,3-4,9-10,19-21H,2,5-8,11-17H2,(H,26,27)(H,28,29)/t20-,21+/m1/s1

HIDE SMILES / InChI

Description
Sources: http://www.drugbank.ca/drugs/DB00492
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/fosinopril.html

Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Angiotensin-converting enzyme 96 Target ID: CHEMBL1808 Sources: http://www.drugbank.ca/drugs/DB00492	Inhibitor 8146		1.0 nM [IC50]
Angiotensin-converting enzyme 96 Target ID: P12822 Gene ID: 1.00009272E8 Gene Symbol: ACE Target Organism: Oryctolagus cuniculus (Rabbit) Sources: https://www.ncbi.nlm.nih.gov/pubmed/2481187	Inhibitor 8146		11.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 546 Sources: https://www.drugs.com/pro/fosinopril.html	Primary		Approved 8307	FOSINOPRIL SODIUM Approved Use Fosinopril sodium tablets are indicated for the treatment of hypertension. They may be used alone or in combination with thiazide diuretics. Fosinopril sodium tablets are indicated in the management of heart failure as adjunctive therapy when added to conventional therapy including diuretics with or without digitalis Launch Date 1.07015039E12

C_max

Value	Dose	Analyte	Population
1556 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2967089/	7.5 mg single, intravenous dose: 7.5 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FOSINOPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
112 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2967089/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	FOSINOPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
533 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1646240/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	FOSINOPRILAT serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
711 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1646240/	40 mg 2 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FOSINOPRILAT serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1018 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1646240/	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	FOSINOPRILAT serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1217 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1646240/	80 mg 2 times / day steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FOSINOPRILAT serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
131 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1646240/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	FOSINOPRILAT serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5598 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1646240/	640 mg single, oral dose: 640 mg route of administration: Oral experiment type: SINGLE co-administered:	FOSINOPRILAT serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
3302 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2967089/	7.5 mg single, intravenous dose: 7.5 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FOSINOPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
920 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2967089/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	FOSINOPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
3.3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1646240/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	FOSINOPRILAT serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1646240/	40 mg 2 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FOSINOPRILAT serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1646240/	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	FOSINOPRILAT serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
7.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1646240/	80 mg 2 times / day steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FOSINOPRILAT serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1646240/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	FOSINOPRILAT serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
58.3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1646240/	640 mg single, oral dose: 640 mg route of administration: Oral experiment type: SINGLE co-administered:	FOSINOPRILAT serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
3.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2967089/	7.5 mg single, intravenous dose: 7.5 mg route of administration: Intravenous experiment type: SINGLE co-administered:		FOSINOPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2967089/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		FOSINOPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
5% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2967089/	7.5 mg single, intravenous dose: 7.5 mg route of administration: Intravenous experiment type: SINGLE co-administered:		FOSINOPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
8% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2967089/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		FOSINOPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
80 mg 1 times / day multiple, oral Highest studied dose Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1534664/	unhealthy, 28 - 68years n = 12 Health Status: unhealthy Condition: essential hypertension Age Group: 28 - 68years Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/1534664/	Sources: https://pubmed.ncbi.nlm.nih.gov/1534664/
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19915se5-037_monopril_lbl.pdf Page: 16	unhealthy, >65 years n = 688 Health Status: unhealthy Condition: hypertension Age Group: >65 years Sex: unknown Population Size: 688 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19915se5-037_monopril_lbl.pdf Page: 16	Disc. AE: Headache, Transaminases increased... AEs leading to discontinuation/dose reduction: Headache (0.4 - 0.9) Transaminases increased (0.4 - 0.9) Fatigue (0.4 - 0.9) Cough (0.4 - 0.9) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19915se5-037_monopril_lbl.pdf Page: 16
40 mg 1 times / day steady, oral MTD Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: https://www.rxlist.com/monopril-drug.htm#description	unhealthy, adult Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Sources: https://www.rxlist.com/monopril-drug.htm#description	Sources: https://www.rxlist.com/monopril-drug.htm#description

AEs

AE	Significance	Dose	Population
Cough	0.4 - 0.9 Disc. AE	20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19915se5-037_monopril_lbl.pdf Page: 16	unhealthy, >65 years n = 688 Health Status: unhealthy Condition: hypertension Age Group: >65 years Sex: unknown Population Size: 688 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19915se5-037_monopril_lbl.pdf Page: 16
Fatigue	0.4 - 0.9 Disc. AE	20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19915se5-037_monopril_lbl.pdf Page: 16	unhealthy, >65 years n = 688 Health Status: unhealthy Condition: hypertension Age Group: >65 years Sex: unknown Population Size: 688 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19915se5-037_monopril_lbl.pdf Page: 16
Headache	0.4 - 0.9 Disc. AE	20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19915se5-037_monopril_lbl.pdf Page: 16	unhealthy, >65 years n = 688 Health Status: unhealthy Condition: hypertension Age Group: >65 years Sex: unknown Population Size: 688 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19915se5-037_monopril_lbl.pdf Page: 16
Transaminases increased	0.4 - 0.9 Disc. AE	20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19915se5-037_monopril_lbl.pdf Page: 16	unhealthy, >65 years n = 688 Health Status: unhealthy Condition: hypertension Age Group: >65 years Sex: unknown Population Size: 688 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19915se5-037_monopril_lbl.pdf Page: 16

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2B6 770 P-gp 1401 BCRP 678 MRP2 363	CYP1A1 344 CYP1A2 1013 CYP2B1 11 CYP2B2 3 CYP2E1 633 CYP3A 188 UGT 183 PEPT1 48

Drug as perpetrator

Target	Modality	Activity
CYP2B6 946	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/17101742/	no
BCRP 751	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/23262422/	yes
MRP2 452	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/23262422/	yes
P-gp 1588	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/23262422/	yes

Drug as victim

Target	Modality	Activity
CYP1A1 344	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/20692951/	no
CYP1A2 1013	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/20692951/	no
CYP2B1 11	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/20692951/	no
CYP2B2 3	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/20692951/	no
CYP2E1 633	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/20692951/	no
PEPT1 48	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/11560874/	yes [Km 154 uM]
CYP3A 188	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/24365260/	yes
UGT 183	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/24365260/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:116962	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:116962
ChemicalBook	CB4711162	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4711162
ZINC	ZINC000004213382	http://zinc15.docking.org/substances/ZINC000004213382

PubMed

Title	Date	PubMed
[Effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in hypertensive rats].	2001 Apr 28	12536639
[Contrast of losartan, fosinopril and amlodipine on cardiomyocyte apoptosis and left ventricular remolding in hypertensive rats].	2001 Oct 28	12536482
The effect and mechanism of forsinopril on ventricular hypertrophy of SHR and left ventricular pressure overloading rat.	2002	12658773
[Changes of distensibility of the aorta in elderly patients during long-term therapy with various classes of hypotensive drugs (magnetic resonance tomography data)].	2002	12494142
Regression of ventricular and vascular hypertrophy: are there differences between structurally different angiotensin-converting enzyme inhibitors?	2002 Dec	12473875
Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism.	2002 Dec	12468576
Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients.	2002 Dec	12460699
[Effect of Erigeron breviscapus injection on ventricular and vascular remodeling in spontaneous hypertension rats].	2002 Feb	12585150
[Renoprotective effect of monopril in patients with diabetes mellitus in the preclinical stage of diabetic nephropathy].	2002 Jul-Sep	12442535
[Comparison of the antihypertensive activity of fosinopril and irbesartan].	2002 Nov	12522893
Optimisation by experimental design of a capillary electrophoretic method for the separation of several inhibitors of angiotensin-converting enzyme using alkylsulphonates.	2002 Nov 29	12458959
FOSIDIAL: a randomised placebo controlled trial of the effects of fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. Study design and patients' baseline characteristics.	2002 Oct	12602460
[Efficacy of combined use of fosinopril and propranolol in acute myocardial infarction].	2003	12891269
[Tongue angioedema associated with angiotensin-converting enzyme inhibitor (diagnosis, differential diagnosis, treatment)].	2003	12829880
[Chronopharmacological approaches to the therapeutic prophylaxis of chronic cardiac insufficiency in type I diabetes mellitus].	2003	12741355
Acute visual loss after initiation of antihypertensive therapy: case report.	2003 Aug 19	12925427
A prospective, randomized, open labeled crossover trial of fosinopril and theophylline in post renal transplant erythrocytosis.	2003 Jan	12617335
Effects of fosinopril and valsartan on expressions of ICAM-1 and NO in human umbilical vein endothelial cells.	2003 Jun	12877808
Effect of xuezhikang, a cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease.	2003 Jun	12801622
ANP but not BNP reflects early left diastolic dysfunction in type 1 diabetics with myocardial dysinnervation.	2003 May	12916000
Angiotensin-converting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis.	2003 Nov	14569096
Protection of organic trauma in sinoaortic-denervated rats treated with fosinopril.	2003 Oct	14730896
Introduction to monitoring. What is what you prescribed actually doing?	2003 Oct	14596082
Dual renin-angiotensin system blockade restores blood pressure-renin dependency in individuals with low renin concentrations.	2003 Oct	14508195
Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition.	2003 Oct	12969167
[Combination therapy with losartan and fosinopril for early diabetic nephropathy].	2003 Sep	13129736
Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy.	2003 Sep	12925048
Precipitation of PTSD with metoprolol for hypertension.	2003 Sep-Oct	12954926
[Effect of fosinopril on the rate of neurohumoral and proinflammatory activation in patients with heart failure].	2004	15540418
[Effects of carvedilol, atenolol and their combination with fosinopril on cardiac rhythm variability, clinicofunctional status and quality of life in patients with postinfarction left ventricular dysfunction].	2004	15532380
Systemic contact dermatitis due to captopril without cross-sensitivity to fosinopril, quinapril and benazepril.	2004	15040496
Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy.	2004 Aug	15302018
Studies on the glycemic and lipidemic effect of monopril and losartan in normal and diabetic rats.	2004 Aug	15177300
Heart failure and first dose hypotension after angiotensin converting enzyme inhibitors.	2004 Dec	15744357
Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind trial.	2004 Dec	15514192
[Changes of collagen expression of pulmonary arteries and heart ventricles and intervention of fosinopril and losartan in rats with heart failure].	2004 Dec 2	15730820
Cardiorenal protective effects of vasopeptidase inhibition with omapatrilat in hypertensive transgenic (mREN-2)27 rats.	2004 Jan	15000298
Fosinopril and amlodipine in the treatment of isolated systolic hypertension.	2004 Jan-Feb	15327190
Comparative effects of fosinopril and irbesartan on hematopoiesis in essential hypertensives.	2004 Jul	15462108
Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect?	2004 Jul 20	15262665
Role of Angiotensin-converting enzyme and neutral endopeptidase in flow-dependent remodeling.	2004 Mar-Apr	15004434
Framingham score and microalbuminuria: combined future targets for primary prevention?	2004 Nov	15485402
Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.	2004 Nov 2	15492322
A unique form of polycythemia associated with minimal change disease.	2004 Nov-Dec	15467313
Lumbar incisional hernias: diagnostic and management dilemma.	2004 Oct-Dec	15554289
Possible induction of diabetes by treatment of hypertension with indapamide (with four case reports).	2004 Sep	15331204
Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes.	2004 Sep	15316457
Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children?	2004 Sep	15262902
Lithium toxicity after switch from fosinopril to lisinopril.	2005 Mar	15729089
Effects of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria.	2005 Mar	15692120

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Hypertension Initial dose: 10 mg orally once a day alone or in combination with a diuretic Maintenance dose: 20 to 40 mg orally once a day; some patients may have further response at 80 mg once a day Usual Adult Dose for Congestive Heart Failure Initial dose: 10 mg orally once a day Target dose range: 20 to 40 mg orally once a day Maximum dose: 40 mg orally once a day

Route of Administration: Oral

In Vitro Use Guide

Fosinopril up-regulated klotho mRNA in NRK-52E cells pretreated with Fos(10(-5) mol/L) for 12 h incubated with AngII

Name

Type

Language

FOSINOPRILAT

Official Name

English

FOSINOPRILAT [USAN]

Common Name

English

FOSINOPRIL RELATED COMPOUND A [USP IMPURITY]

Common Name

English

(4S)-4-CYCLOHEXYL-1-((HYDROXY(4-PHENYLBUTYL)PHOSPHINYL)ACETYL)-L-PROLINE

Systematic Name

English

fosinoprilat [INN]

Common Name

English

SQ 27,519

Code

English

PU6BA2D2MD

Code

English

L-PROLINE, 4-CYCLOHEXYL-1-((HYDROXY(4-PHENYLBUTYL)PHOSPHINYL)ACETYL)-, TRANS-

Systematic Name

English

(2S,4S)-4-CYCLOHEXYL-1-((HYDROXY(4-PHENYLBUTYL)PHOSPHORYL)ACETYL)PYRROLIDINE-2-CARBOXYLIC ACID

Systematic Name

English

FOSINOPRIL SODIUM IMPURITY A [EP IMPURITY]

Common Name

English

FOSINOPRILIC ACID

Common Name

English

FOSFENOPRIL

Common Name

English

SQ-27519

Code

English

FOSINOPRIL DIACID [MI]

Common Name

English

FOSINOPRIL RELATED COMPOUND A [USP-RS]

Common Name

English

FOSINOPRIL DIACID

Common Name

English

SO-27519

Code

English

Classification Tree Code System Code

NDF-RT

N0000175562